Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • IL-13 inhibitor

    - PMLiVE

    AstraZeneca shares late-stage results for Airsupra in mild asthma patients

    More than ten million asthma exacerbations occur in the US every year

    - PMLiVE

    AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

    Up to 262 million people worldwide are affected by the chronic respiratory disease

    - PMLiVE

    AstraZeneca announces $2.5bn investment in China to boost R&D capabilities

    The funds will go towards a new global research and development centre in Beijing’s BioPark

    - PMLiVE

    AstraZeneca to expand cell therapy capabilities with $1bn EsoBiotec acquisition

    The biotech’s ENaBL platform enables cell therapies to be administered through an IV injection

    - PMLiVE

    Chiesi report highlights incorrect inhaler use among UK asthma patients

    The long-term lung condition affects around 7.2 million people in the UK

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    - PMLiVE

    AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

    The chronic respiratory disease is estimated to affect up to 262 million people globally

    - PMLiVE

    GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition

    The deal includes a monoclonal antibody ready to enter phase 2 development for asthma

    - PMLiVE

    AstraZeneca’s mild combination asthma reliever approved in UK

    Over two and a half million adults with mild cases of asthma could be eligible for the treatment

    - PMLiVE

    AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval

    Airsupra significantly reduces the risk of severe asthma exacerbations

    - PMLiVE

    AZ and Avillion’s asthma rescue treatment recommended by FDA Advisory Committee

    PT027 significantly reduced the risk of severe asthma exacerbations

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links